HR 1825
118th Congress
House
Health
Right to Try Clarification Act
Introduced: March 28, 2023
See on congress.gov
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 7, 2023
Referred to the Subcommittee on Health.
Mar 28, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 28, 2023
Sponsor introductory remarks on measure. (CR E267)
Mar 28, 2023
Introduced in House
Plain-English summary
Right to Try Clarification Act
This bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).
The Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
3